At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 50 enrolled
Drug / intervention
TAK-831 Tablet T2 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Investigator and Subject Blinded, Sponsor Unblinded Placebo-Controlled Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating TAK-831 Tablet T2, Placebo, and 1 other intervention for Healthy. Completed, enrolled 50 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and tolerability of TAK-831 when administered as multiple oral doses at escalating dose levels in healthy participants.
Study Details
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartJul 2017
Primary CompletionSep 2018
TodayJul 2026
First PostedJul 21, 2017
Enrollment StartJul 21, 2017
Primary CompletionSep 9, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.9 years ago
Interventions
TAK-831 Tablet T2drug
Tak-831 tablets.
Placebodrug
TAK-831 placebo-matching suspension.
TAK-831 Suspensiondrug
TAK-831 Suspension.